IXICO plc (LSE:IXI) posted strong results for the year ended September 2025, reporting a 13% rise in revenue and a 21% improvement in EBITDA loss, reflecting continued progress under its Innovate Lead Scale strategy. The company strengthened its order book, expanded its North American presence, and further diversified its revenue mix while enhancing capabilities across its AI-enabled neuroimaging platform. These developments reinforce IXICO’s position as a leading player in neuroimaging and biomarker analytics, supporting efforts to accelerate drug development for neurological diseases and creating added value for stakeholders.

Following the announcement, IXICO’s shares rose 4%.

The company also confirmed that its Annual General Meeting will take place on 23 January 2026.

More about IXICO plc

IXICO plc is a global specialist in neuroscience imaging and biomarker analytics, leveraging an AI-driven platform to advance the understanding and treatment of neurological conditions. Operating as an Imaging Contract Research Organisation (iCRO), IXICO partners with pharmaceutical companies, biotechs, and non-profits to support clinical trials focused on disorders such as Alzheimer’s, Huntington’s, and Parkinson’s. The company provides precise imaging biomarker measurement to accelerate drug discovery and development.

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.
Some portions of this content may have been generated or assisted by artificial intelligence (AI) tools and been reviewed for accuracy and quality by our editorial team.